-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Reiterates Buy on Biogen, Raises Price Target to $260

Benzinga·10/29/2026 14:37:21
語音播報
Truist Securities analyst Danielle Brill reiterates Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $235 to $260.